Provention Bio Inc (NASDAQ:PRVB) stock continues to make a big move in the pre-market on Tuesday after the news.
Provention Bio indicated higher ahead of the bell as FDA’s Endocrinologic and Metabolic Drugs Advisory Committee publishes Briefing docs on teplizumab; meeting to begin May 27 at 9 a.m.
At the time of writing, PRVB stock is up by 35.46% to $10.81. The stock went up over 15% as well last week.
earlier this month, the company reported first-quarter earnings. Net loss for the first quarter 2021 was $32.4 million, or $0.52 per basic and diluted share, compared to a net loss of $12.6 million, or $0.26 per basic and diluted share, for the same period in 2020. As of March 31, 2021, Provention Bio had cash and cash equivalents and marketable securities of $207.2 million. In the first quarter, the Company completed an underwritten public offering that generated aggregate net proceeds of $102.3 million.
Biotech, Tech, and Crypto reporter
Anthony Gonzales brings 3 years of experience in helping grassroots, mid-sized organizations and large institutions strengthen their management and resource generating capacities and effectively plan for the future. He is also a mentor and professional advisor to artists working in all disciplines. He is the gold medalist from St. Marco University of Science and Technology in the Bachelors of Financial Management as well.